Alexander Cumbo
CIK 1685994 · President and CEO · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.30M
Companies
6
Total Filings
46
Lifetime Open-Market Net
-$13.38M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VOR | Director | — | $23.59 | — | $0 | 2 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 3 | 2026-06-08 |
| SLDB | President and CEO | 235,405 | $8.85 | $2.08M | -$1.12M | 12 | 2026-04-21 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 5 | 2025-07-28 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 3 | 2020-04-03 |
| SRPT | EVP, Chief Commercial Officer | 12,008 | $18.22 | $218.8K | -$12.25M | 14 | 2020-02-28 |
Recent Filings · Page 4 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-02-28 | SRPT | Grant (A) | +6,700 | $0 | EDGAR |
| 2019-12-17 | SRPT | Mixed | −9,294 | -$4.50M | EDGAR |
| 2019-06-13 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-29 | SRPT | Mixed | +2,711 | -$256.9K | EDGAR |
| 2019-03-04 | SRPT | Mixed | −3,375 | $0 | EDGAR |
| 2019-02-01 | SRPT | Mixed | −7,500 | -$1.93M | EDGAR |
| 2018-11-15 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-08-08 | SRPT | Tax (F) | −6,000 | -$726.1K | EDGAR |
| 2018-07-11 | SRPT | Mixed | — | -$4.17M | EDGAR |
| 2018-05-24 | SRPT | Mixed | +3,441 | -$128.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.